连续裸金属支架腔内治疗长段股腘动脉病变的疗效
单中心回顾性分析64例长段股腘动脉病变(长度>250 mm)患者,采用连续裸金属支架腔内治疗,12个月一期通畅率为66.6%,6个月和24个月分别为79.7%和60.9%,30天死亡率为零,结论认为该策略对严重肢体缺血且预期寿命有限的患者是可接受的替代方案。
要点
- 长段股腘动脉病变连续裸金属支架12个月一期通畅率66.6%。
- 严重肢体缺血患者占76.6%,组织缺损愈合率77.5%。
- 30天死亡率为零,但随访期间死亡率达34.3%。
核心结论
- 连续裸金属支架腔内治疗长段股腘动脉病变的12个月一期通畅率可接受,可作为严重肢体缺血且预期寿命有限患者的替代策略。
研究设计与样本
- 单中心回顾性研究,2014年1月至2017年12月共1233例患者接受腹股沟下血管成形术,筛选出64例股腘动脉病变长度>250 mm并采用连续裸金属支架治疗的患者。
- 连续数据以均数和标准差表示,生存分析采用Kaplan-Meier法。
主要发现
- 患者年龄80±11岁,49例(76.6%)表现为严重肢体缺血,54.7%的病变为TASC D级。
- 病变长度295±64 mm,植入支架3±1枚。
- 30天死亡率为零,2例(3.1%)出现非血管性重大并发症。
- 随访27±17个月期间,22例(34.3%)死亡,其中3例死于血管原因。
- 组织缺损愈合率77.5%,截肢率10.9%。
临床怎么用
- 对于长段股腘动脉病变合并严重肢体缺血且预期寿命有限的患者,可考虑采用连续裸金属支架腔内治疗。
- 术后需密切随访靶病变通畅情况,12个月一期通畅率约66.6%,必要时行靶病变血运重建。
局限性
- 单中心回顾性研究,样本量较小(64例),可能存在选择偏倚。
- 缺乏与其他治疗方式(如药物涂层支架/球囊)的对照比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Recent controversies on the use of drug coated/eluting devices in the arteries of the lower extremities renewed the focus on the evaluation of more conventional techniques. The results of the stenting of short and/or intermediate femoro-popliteal lesions are well known, but little data relate to the endovascular treatment of long femoro-popliteal lesions with contiguous bare metal stents (ETLFBS). The objective of this study was to report our results of ETLFBS. MATERIAL AND METHODS: Between January 2014 and December 2017, 1233 patients had an infrainguinal angioplasty in our center. The files of patients treated for femoropopliteal lesions longer than 250 mm using extensive stenting with contiguous bare metal stents were reviewed and analyzed. The primary outcome was the 12-month primary patency, defined by the absence of restenosis (≥50%) and/or reintervention on the target lesion. Continuous data were expressed as mean and standard deviation. Survival analysis was carried out according to Kaplan-Meier. RESULTS: Overall, 64 patients aged 80 ± 11 years were included, with 49 (76.6%) presenting with critical limb ischemia. Lesions were classified as TASC D in 54.7% of the cases. The length of the lesions was 295 ± 64 mm and 3 ± 1 stents were implanted. The 30-day mortality was null but two patients (3.1%) presented nonvascular major complications. With a follow-up of 27 ± 17 months, 22 patients (34.3%) died including three of vascular causes. The healing of the trophic disorder was obtained in 77.5% of the cases. The rate of amputation was 10.9%. The 6-, 12-, and 24-month primary patency rates were 79.7%, 66.6%, and 60.9%, respectively. The 6-, 12-, and 24-month rates of freedom from target lesion revascularization were 96.3%, 73.9%, and 71.9%, respectively. The 6-, 12-, and 24-month survival rates were 90.3%, 83.6%, and 65.6%, respectively. CONCLUSIONS: The 12-month primary patency rate of ETLFBS is acceptable. This strategy constitutes an acceptable alternative in patients presenting with critical limb ischemia and a limited life expectancy.
引用
- Labed P, Gonzalez F, Jayet J, et al. Endovascular Treatment of Long Femoropopliteal Lesions with Contiguous Bare Metal Stents. Ann Vasc Surg. 2021. PMID: 34175412. doi:10.1016/j.avsg.2021.04.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。